TABLE 1.
Baseline characteristics of all liver and kidney transplant recipients
| All SOT recipients, n = 1428 | Liver transplant recipients, n = 523 (36.6%) | Kidney transplant recipients, n = 905 (63.4%) | |
| Age, median (IQR) | 54 (45–63) | 55 (46–63) | 53 (44–63) |
| Sex (male), n (%) | 851 (59.6%) | 294 (56.2%) | 557 (61.5%) |
| Time since transplantation at end of follow-up in years, median (IQR) | 6.1 (2.6–10.4) | 5.1 (1.8–9.7) | 6.6 (3.0–10.7) |
| Comorbidities, n (%) | |||
| Cardiovascular diseasea | 717 (68.5%) | 145 (36.2%) | 572 (88.5%) |
| Chronic pulmonary disease | 115 (11.0%) | 42 (10.5%) | 73 (11.3%) |
| Diabetes mellitus | 253 (24.2%) | 89 (22.2%) | 164 (25.4%) |
| Immunosuppressive treatment, n (%) | |||
| No antimetabolites | 206 (14.4%) | 121 (23.1%) | 85 (9.4%) |
| Mycophenolate | 1095 (76.7%) | 366 (70.0%) | 729 (80.6%) |
| Azathioprine | 127 (8.9%) | 36 (6.9%) | 91 (10.1%) |
| Calcineurin inhibitor (Ciclosporin, Tacrolimus) | 1277 (89.4%) | 475 (90.8%) | 802 (88.6%) |
| mTOR inhibitor (Sirolimus, Everolimus) | 86 (6.0%) | 32 (6.1%) | 54 (6.0%) |
| Corticosteroids | 1082 (75.8%) | 256 (48.9%) | 826 (91.3%) |
| Number of vaccine doses at time of death or December 27, 2021 | |||
| 0 | 74 (5.2%) | 21 (4.0%) | 53 (5.9%) |
| 1 | 5 (0.4%) | 3 (0.6%) | 2 (0.2%) |
| 2 | 127 (8.9%) | 45 (8.6%) | 82 (9.1%) |
| 3 | 1222 (85.6%) | 454 (86.8%) | 768 (84.9%) |
Abbreviations: IQR, interquartile range; mTOR, mammalian target of rapamycin.
a
Missing data from 381 participants (122 liver transplant recipients and 259 kidney transplant recipients).